Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.
Adolescent
Betacoronavirus
COVID-19
Child
Child, Preschool
Cohort Studies
Coronavirus Infections
/ diagnosis
Diagnosis, Differential
Female
Humans
Male
Mucocutaneous Lymph Node Syndrome
/ diagnosis
Pandemics
Paris
/ epidemiology
Pneumonia, Viral
/ diagnosis
SARS-CoV-2
Systemic Inflammatory Response Syndrome
/ diagnosis
cytokines
inflammation
outcome and process assessment, health care
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
12
05
2020
revised:
27
05
2020
accepted:
02
06
2020
pubmed:
13
6
2020
medline:
23
7
2020
entrez:
13
6
2020
Statut:
ppublish
Résumé
Current data suggest that COVID-19 is less frequent in children, with a milder course. However, over the past weeks, an increase in the number of children presenting to hospitals in the greater Paris region with a phenotype resembling Kawasaki disease (KD) has led to an alert by the French national health authorities. Multicentre compilation of patients with KD in Paris region since April 2020, associated with the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ('Kawa-COVID-19'). A historical cohort of 'classical' KD served as a comparator. Sixteen patients were included (sex ratio=1, median age 10 years IQR (4·7 to 12.5)). SARS-CoV-2 was detected in 12 cases (69%), while a further three cases had documented recent contact with a quantitative PCR-positive individual (19%). Cardiac involvement included myocarditis in 44% (n=7). Factors prognostic for the development of severe disease (ie, requiring intensive care, n=7) were age over 5 years and ferritinaemia >1400 µg/L. Only five patients (31%) were successfully treated with a single intravenous immunoglobulin (IVIg) infusion, while 10 patients (62%) required a second line of treatment. The Kawa-COVID-19 cohort differed from a comparator group of 'classical' KD by older age at onset 10 vs 2 years (p<0.0001), lower platelet count (188 vs 383 G/L (p<0.0001)), a higher rate of myocarditis 7/16 vs 3/220 (p=0.0001) and resistance to first IVIg treatment 10/16 vs 45/220 (p=0.004). Kawa-COVID-19 likely represents a new systemic inflammatory syndrome temporally associated with SARS-CoV-2 infection in children. Further prospective international studies are necessary to confirm these findings and better understand the pathophysiology of Kawa-COVID-19.
Sections du résumé
BACKGROUND
Current data suggest that COVID-19 is less frequent in children, with a milder course. However, over the past weeks, an increase in the number of children presenting to hospitals in the greater Paris region with a phenotype resembling Kawasaki disease (KD) has led to an alert by the French national health authorities.
METHODS
Multicentre compilation of patients with KD in Paris region since April 2020, associated with the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ('Kawa-COVID-19'). A historical cohort of 'classical' KD served as a comparator.
RESULTS
Sixteen patients were included (sex ratio=1, median age 10 years IQR (4·7 to 12.5)). SARS-CoV-2 was detected in 12 cases (69%), while a further three cases had documented recent contact with a quantitative PCR-positive individual (19%). Cardiac involvement included myocarditis in 44% (n=7). Factors prognostic for the development of severe disease (ie, requiring intensive care, n=7) were age over 5 years and ferritinaemia >1400 µg/L. Only five patients (31%) were successfully treated with a single intravenous immunoglobulin (IVIg) infusion, while 10 patients (62%) required a second line of treatment. The Kawa-COVID-19 cohort differed from a comparator group of 'classical' KD by older age at onset 10 vs 2 years (p<0.0001), lower platelet count (188 vs 383 G/L (p<0.0001)), a higher rate of myocarditis 7/16 vs 3/220 (p=0.0001) and resistance to first IVIg treatment 10/16 vs 45/220 (p=0.004).
CONCLUSION
Kawa-COVID-19 likely represents a new systemic inflammatory syndrome temporally associated with SARS-CoV-2 infection in children. Further prospective international studies are necessary to confirm these findings and better understand the pathophysiology of Kawa-COVID-19.
Identifiants
pubmed: 32527868
pii: annrheumdis-2020-217960
doi: 10.1136/annrheumdis-2020-217960
pmc: PMC7299653
doi:
Banques de données
ClinicalTrials.gov
['NCT02377245']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1006Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Heart. 2020 Mar;106(6):411-420
pubmed: 31843876
Immunity. 2019 Sep 17;51(3):508-521.e6
pubmed: 31471109
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213
pubmed: 32215952
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Pediatrics. 2009 May;123(5):e783-9
pubmed: 19403470
J Allergy Clin Immunol. 2020 Jul;146(1):206-208.e2
pubmed: 32360285
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Clin Rev Allergy Immunol. 2020 Aug;59(1):122-139
pubmed: 32200494
Rheumatol Int. 2019 Oct;39(10):1797-1801
pubmed: 31302740
Arthritis Rheumatol. 2017 Feb;69(2):268-276
pubmed: 27792871
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Clin Chim Acta. 2020 Jul;506:222-227
pubmed: 32156603
Sci Rep. 2020 Feb 20;10(1):3125
pubmed: 32080307
N Engl J Med. 2020 Jul 9;383(2):187-190
pubmed: 32356945
Cardiol Res. 2020 Feb;11(1):9-14
pubmed: 32095191
Front Med (Lausanne). 2021 Jan 14;7:560685
pubmed: 33521004
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
Laryngoscope. 2020 Jul;130(7):1787
pubmed: 32237238
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Pediatr Rheumatol Online J. 2018 Jul 18;16(1):48
pubmed: 30021610
Arthritis Rheumatol. 2019 May;71(5):792-804
pubmed: 30447136
Ann Rheum Dis. 2016 Mar;75(3):481-9
pubmed: 26865703
Autoimmun Rev. 2018 Aug;17(8):768-774
pubmed: 29885546
Int J Rheum Dis. 2018 Jan;21(1):45-49
pubmed: 29105303
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Circulation. 2020 Aug 4;142(5):429-436
pubmed: 32418446
Hosp Pediatr. 2020 Jun;10(6):537-540
pubmed: 32265235
Front Immunol. 2019 Mar 21;10:185
pubmed: 30949161
Pediatrics. 2020 Aug;146(2):
pubmed: 32439816
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
JAMA Pediatr. 2020 Sep 01;174(9):882-889
pubmed: 32320004
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613